Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29:10:1209614.
doi: 10.3389/fnut.2023.1209614. eCollection 2023.

The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis

Jiajun Liu  1   2 , Haodong Su  1   2 , Xueshan Jin  3 , Lan Wang  1   2 , Jieming Huang  1   2
Affiliations

The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis

Jiajun Liu et al. Front Nutr. .

Abstract

Objectives: Polycystic ovary syndrome (PCOS) is a common endocrine disease, often accompanied by metabolic disorders. Metformin, as an insulin sensitizer, is widely used to improve the metabolic function of PCOS, but may have gastrointestinal side effects. Emerging evidence suggests that N-acetylcysteine (NAC) improves metabolic parameters in PCOS and may be a potential alternative to metformin.

Methods: We searched four online databases, PubMed, Embase, Web of Science, and Cochrane Library, from inception to April 1, 2023. The I2 statistic and Cochrane's Q test were employed to determine heterogeneity between studies, with an I2 value >50% or p < 0.1 considered significant. The data were expressed as standardized mean differences and corresponding 95% confidence intervals.

Results: A total of 11 randomized controlled trials were included in the final analysis, including 869 women with PCOS. The results showed that NAC caused more changes in body mass index (SMD: -0.16, 95% CI: -0.40 to 0.08), body weight (SMD: -0.25, 95% CI: -0.50 to 0.00), fasting insulin (SMD: -0.24, 95% CI: -0.53 to 0.06), ratio of fasting blood glucose to fasting insulin (SMD: 0.38, 95% CI: -0.33 to 1.08), total cholesterol (SMD: -0.11, 95% CI: -0.39 to 0.17), triglycerides (SMD: -0.18, 95% CI: -0.63 to 0.28), and low-density lipoprotein (SMD: -0.09, 95% CI: -0.51 to 0.33) compared with metformin. Compared with metformin or placebo, NAC significantly reduced fasting blood-glucose levels (SMD: -0.23, 95% CI: -0.43 to -0.04; SMD: -0.54, 95% CI: -1.03 to -0.05, respectively). In addition, NAC significantly reduced total cholesterol (SMD: -0.74, 95% CI: -1.37 to -0.12), and this effect was observed when NAC was compared with placebo. However, NAC reduced HDL levels in women with PCOS compared with metformin (SMD: -0.14, 95% CI: -0.42 to 0.14).

Conclusion: This study suggests that NAC is effective in improving metabolic parameters in PCOS and may be a promising nutritional supplement for the treatment of PCOS.Systematic review registration:https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=415172, identifier CRD42022339171.

Keywords: N-acetylcysteine; meta-analysis; metabolic parameters; nutritional supplementation; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart for searching and selection details.
Figure 2
Figure 2
Forest plots of comparing NAC with metformin or placebo on BMI.
Figure 3
Figure 3
Forest plots of comparing NAC with metformin or placebo on weight.
Figure 4
Figure 4
Forest plots of comparing NAC with metformin or placebo on fasting blood glucose (FBG).
Figure 5
Figure 5
Forest plots of comparing NAC with metformin or placebo on fasting insulin (FI).
Figure 6
Figure 6
Forest plots of comparing NAC with metformin or placebo on the ratio of fasting blood glucose to fasting insulin (FBG/FI).
Figure 7
Figure 7
Forest plots of comparing NAC with metformin or placebo on total cholesterol (TC).
Figure 8
Figure 8
Forest plots of comparing NAC with metformin or placebo on triglyceride (TG).
Figure 9
Figure 9
Forest plots of comparing NAC with metformin or placebo on low density lipoprotein (LDL).
Figure 10
Figure 10
Forest plots of comparing NAC with metformin or placebo on high density lipoprotein (HDL).
See this image and copyright information in PMC

References

    1. Neven ACH, Laven J, Teede HJ, Boyle JA. A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. Semin Reprod Med. (2018) 36:5–12. doi: 10.1055/s-0038-1668085 - DOI - PubMed
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. (2004) 81:19–25. doi: 10.1016/j.fertnstert.2003.10.004, PMID: - DOI - PubMed
    1. Shrivastava S, Conigliaro RL. Polycystic ovarian syndrome. Med Clin North Am. (2023) 107:227–34. doi: 10.1016/j.mcna.2022.10.004, PMID: - DOI - PubMed
    1. Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ. Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews. Clin Endocrinol. (2018) 89:683–99. doi: 10.1111/cen.13828, PMID: - DOI - PubMed
    1. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. (2020) 30:399–404. doi: 10.1016/j.tcm.2019.08.010, PMID: - DOI - PubMed

Publication types